AJCN Yamada Bee Farm Grant for Honeybee Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hukshorn, C. J
Right arrow Articles by Saris, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hukshorn, C. J
Right arrow Articles by Saris, W. H.
Agricola
Right arrow Articles by Hukshorn, C. J
Right arrow Articles by Saris, W. H.
American Journal of Clinical Nutrition, Vol. 77, No. 4, 771-776, April 2003
© 2003 American Society for Clinical Nutrition


Original Research Communication

Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men1,2,3

Chris J Hukshorn, Margriet S Westerterp-Plantenga and Wim HM Saris

1 From the Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Human Biology, Maastricht University, Maastricht, Netherlands.

Background: Increasing evidence suggests that falling leptin concentrations observed during fasting act as a peripheral signal of starvation, which serves to conserve energy in the face of limited reserves. An extension of this hypothesis is that exogenous leptin should affect energy regulation during severe energy restriction.

Objective: To explore this hypothesis, we assessed whether elevated leptin concentrations achieved with the use of long-acting pegylated human recombinant leptin [polyethylene glycol–OB protein (PEG-OB)] affected weight loss and changes in body composition, energy expenditure, appetite, and metabolic variables during semistarvation in healthy overweight men.

Design: A randomized, double-blind, placebo-controlled study was executed in overweight men with a mean (± SEM) age of 34.8 ± 1.3 y and body mass index (in kg/m2) of 28.8 ± 0.5. All subjects received weekly treatment with 80 mg PEG-OB (n = 12) or matching placebo (n = 10) for 46 d while their energy intake was reduced to 2.1 MJ/d by means of a very-low-energy diet. Body composition (hydrodensitometry and deuterium dilution), energy expenditure (ventilated hood), and appetite (visual analogue scales) were evaluated at the start and the end of the study. Metabolic variables were measured throughout the study period.

Results: Compared with placebo treatment, treatment with PEG-OB led to significant (P < 0.03) additional weight loss (14.6 ± 0.8 compared with 11.8 ± 0.9 kg) and a reduction in appetite (P < 0.05) after 46 d, but the 2 treatment groups did not differ significantly in changes in body composition, energy expenditure, and metabolic variables.

Conclusion: Our observations support the hypothesis that the decrease in leptin concentrations during starvation increases appetite in humans.

Key Words: Leptin, pegylated human recombinant leptin, polyethylene glycol • OB protein, PEG-OB, semistarvation, very-low-energy diet, body composition, energy expenditure, appetite, weight loss, men




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Kersten, L. Lichtenstein, E. Steenbergen, K. Mudde, H. F.J. Hendriks, M. K. Hesselink, P. Schrauwen, and M. Muller
Caloric Restriction and Exercise Increase Plasma ANGPTL4 Levels in Humans via Elevated Free Fatty Acids
Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 969 - 974.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
G. A. Bray and F. L. Greenway
Pharmacological Treatment of the Overweight Patient
Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Mandard, F. Zandbergen, N. S. Tan, P. Escher, D. Patsouris, W. Koenig, R. Kleemann, A. Bakker, F. Veenman, W. Wahli, et al.
The Direct Peroxisome Proliferator-activated Receptor Target Fasting-induced Adipose Factor (FIAF/PGAR/ANGPTL4) Is Present in Blood Plasma as a Truncated Protein That Is Increased by Fenofibrate Treatment
J. Biol. Chem., August 13, 2004; 279(33): 34411 - 34420.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
C. de Graaf, W. A. Blom, P. A. Smeets, A. Stafleu, and H. F. Hendriks
Biomarkers of satiation and satiety
Am. J. Clinical Nutrition, June 1, 2004; 79(6): 946 - 961.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Korner and L. J. Aronne
Pharmacological Approaches to Weight Reduction: Therapeutic Targets
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2616 - 2621.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. J. Hukshorn, J. H. N. Lindeman, K. H. Toet, W. H. M. Saris, P. H. C. Eilers, M. S. Westerterp-Plantenga, and T. Kooistra
Leptin and the Proinflammatory State Associated with Human Obesity
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1773 - 1778.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by The American Society for Nutrition